

Ref. No: 2084  
Date: 02/10/25  
Subject: Dermatology and respiratory medicine

## REQUEST & RESPONSE

How many patients were treated in September 2025 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo) 7
- Baricitinib (Olumiant) 11
- Dupilumab (Dupixent) 39
- Lebrikizumab (Ebglyss) <5
- Omalizumab (Xolair) 13
- Tralokinumab (Adtralza) <5
- Upadacitinib (Rinvoq) 10
- Nemolizumab (Nemluvio) 0

How many patients were treated in September 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs:

- Benralizumab (Fasenra) 0
- Dupilumab (Dupixent) 0
- Mepolizumab (Nucala) 0
- Omalizumab (Xolair) 7
- Reslizumab (Cinqaero) 0
- Tezepelumab (Tezspire) 0

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).